ASCO 2023 | Addressing unmet needs in head and neck squamous cell carcinoma

Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH, provides an overview of unmet needs in head and neck squamous cell carcinoma. For patients who are PD-L1-positive, the addition of chemotherapy is associated with increased toxicity, and BCA101, an EGFR/TGFβ inhibitor, is a promising therapeutic option. However, more research is needed to elucidate novel treatments for patients with PD-L1-negative head and neck cancers. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.